139 related articles for article (PubMed ID: 37621013)
1. Key factors associated with 6-thioguanine and 6-methylmercaptopurine nucleotide concentrations in children treated by thiopurine for acute leukaemia and inflammatory bowel disease.
de Beaumais TA; Lorrain S; Mamhoudi N; Simonin M; Martinez Vinson C; Medard Y; Petit A; Jacqz-Aigrain E
Br J Clin Pharmacol; 2024 Jan; 90(1):209-219. PubMed ID: 37621013
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine.
Hawwa AF; Millership JS; Collier PS; Vandenbroeck K; McCarthy A; Dempsey S; Cairns C; Collins J; Rodgers C; McElnay JC
Br J Clin Pharmacol; 2008 Oct; 66(4):517-28. PubMed ID: 18662289
[TBL] [Abstract][Full Text] [Related]
3. Improved methods for determining the concentration of 6-thioguanine nucleotides and 6-methylmercaptopurine nucleotides in blood.
Pike MG; Franklin CL; Mays DC; Lipsky JJ; Lowry PW; Sandborn WJ
J Chromatogr B Biomed Sci Appl; 2001 Jun; 757(1):1-9. PubMed ID: 11419732
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease.
Belaiche J; Desager JP; Horsmans Y; Louis E
Scand J Gastroenterol; 2001 Jan; 36(1):71-6. PubMed ID: 11218242
[TBL] [Abstract][Full Text] [Related]
5. Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.
Lennard L; Cartwright CS; Wade R; Richards SM; Vora A
Br J Clin Pharmacol; 2013 Jul; 76(1):125-36. PubMed ID: 23252716
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
[TBL] [Abstract][Full Text] [Related]
7. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
Chouchana L; Narjoz C; Beaune P; Loriot MA; Roblin X
Aliment Pharmacol Ther; 2012 Jan; 35(1):15-36. PubMed ID: 22050052
[TBL] [Abstract][Full Text] [Related]
8. The Impact of Thiopurine Metabolite Monitoring on the Durability of Thiopurine Monotherapy in Pediatric IBD.
Spencer E; Norris E; Williams C; Dubinsky MC
Inflamm Bowel Dis; 2019 Jan; 25(1):142-149. PubMed ID: 29920603
[TBL] [Abstract][Full Text] [Related]
9. Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate.
Pettersson B; Almer S; Albertioni F; Söderhäll S; Peterson C
Ther Drug Monit; 2002 Jun; 24(3):351-8. PubMed ID: 12021625
[TBL] [Abstract][Full Text] [Related]
10. Proactive Metabolite Testing in Patients on Thiopurine May Yield Long-Term Clinical Benefits in Inflammatory Bowel Disease.
Barnes A; Ooi SJ; Lynch KD; Parthasarathy N; Bishara M; Gounder M; Grafton R; Leach P; Bampton P; Sechi A; Ng W; Connor S; van Langenberg D; Mountifield R; Andrews JM
Dig Dis Sci; 2023 Mar; 68(3):889-896. PubMed ID: 35687221
[TBL] [Abstract][Full Text] [Related]
11. A validated HPLC method for the monitoring of thiopurine metabolites in whole blood in paediatric patients with inflammatory bowel disease.
Cangemi G; Barabino A; Barco S; Parodi A; Arrigo S; Melioli G
Int J Immunopathol Pharmacol; 2012; 25(2):435-44. PubMed ID: 22697075
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic drug monitoring of thiopurines: Effect of reduced 6-thioguanine nucleotide target levels in inflammatory bowel disease patients.
Boekema M; Horjus-Talabur Horje CS; Roosenboom B; Roovers L; van Luin M
Br J Clin Pharmacol; 2022 Aug; 88(8):3741-3748. PubMed ID: 35293629
[TBL] [Abstract][Full Text] [Related]
13. Nucleoside diphosphate-linked moiety X-type motif 15 R139C genotypes impact 6-thioguanine nucleotide cut-off levels to predict thiopurine-induced leukopenia in Crohn's disease patients.
Zhu X; Chao K; Li M; Xie W; Zheng H; Zhang JX; Hu PJ; Huang M; Gao X; Wang XD
World J Gastroenterol; 2019 Oct; 25(38):5850-5861. PubMed ID: 31636477
[TBL] [Abstract][Full Text] [Related]
14. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing.
Teml A; Schaeffeler E; Herrlinger KR; Klotz U; Schwab M
Clin Pharmacokinet; 2007; 46(3):187-208. PubMed ID: 17328579
[TBL] [Abstract][Full Text] [Related]
15. Systematic review with meta-analysis: risk factors for thiopurine-induced leukopenia in IBD.
van Gennep S; Konté K; Meijer B; Heymans MW; D'Haens GR; Löwenberg M; de Boer NKH
Aliment Pharmacol Ther; 2019 Sep; 50(5):484-506. PubMed ID: 31342537
[TBL] [Abstract][Full Text] [Related]
16. [Therapeutic drug monitoring of 6-thioguanine nucleotides in inflammatory bowel disease: interest and limits].
Jourdil N; Fonrose X; Boulieu R; Stanke-Labesque F;
Therapie; 2010; 65(3):177-86. PubMed ID: 20699068
[TBL] [Abstract][Full Text] [Related]
17. Late-onset Rise of 6-MMP Metabolites in IBD Patients on Azathioprine or Mercaptopurine.
Munnig-Schmidt E; Zhang M; Mulder CJ; Barclay ML
Inflamm Bowel Dis; 2018 Mar; 24(4):892-896. PubMed ID: 29522107
[TBL] [Abstract][Full Text] [Related]
18. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
Gearry RB; Barclay ML
J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease.
Hindorf U; Lyrenäs E; Nilsson A; Schmiegelow K
Scand J Gastroenterol; 2004 Nov; 39(11):1105-12. PubMed ID: 15545169
[TBL] [Abstract][Full Text] [Related]
20. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine.
Dubinsky MC; Feldman EJ; Abreu MT; Targan SR; Vasiliauskas EA
Am J Gastroenterol; 2003 May; 98(5):1058-63. PubMed ID: 12809828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
